MedTrace Logo

Familial Pancreatic Cancer PROPHilation Program in Italy

NCT05724992 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2023-02-15

No results posted yet for this study

Summary

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.

Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.

Up to 3,000 participants will be enrolled in this study.

Conditions

  • Candidates for Hereditary Pancreatic Cancer Testing

Interventions

GENETIC

Saliva swab testing

41 pancreatic cancer predisposition genes will be tested through a saliva-based swab

Sponsors & Collaborators

  • General and Pancreatic Surgery Unit, University of Verona

    collaborator UNKNOWN

  • Fondazione Valsecchi

    collaborator UNKNOWN

  • Associazione Oltre La Ricerca

    collaborator UNKNOWN

  • Genomica srl

    collaborator UNKNOWN

  • Associazione Italiana per lo Studio del Pancreas

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2027-12-20
Completion
2028-12-20

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05724992 on ClinicalTrials.gov